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Abstract
Inhibitors are the most serious side effect of haemophilia treatment; they occur in 25–30 % of all patients with
severe haemophilia A. Over the last 2 decades, conflicting data on the impact of clotting products have been
published.
Due to small studies of selected cases, appreciation of the impact of any particular product has been difficult.
Moreover, the emphasis on inhibitor testing has led to increased detection of low-titre inhibitors (to >10 %), while
the percentage of high-titre inhibitors is still around 20 %.
Other non-genetic risk factors, such as dosing and intensive treatment, are able to increase individual inhibitor risk.
Early prophylaxis might reduce inhibitor risk. Well-defined large PUP studies including products should be
considered. This can only be achieved in collaboration with all stakeholders.
In conclusion, while the impact of FVIII products on inhibitor development is large, presently the actual impact of
any specific product is unclear.
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Background
The development of inhibitory antibodies in severe
haemophilia A is the major side effect of treatment. In
patients with severe haemophilia A, 25–30 % will de-
velop antibodies [1, 2]. From the start, the direct correl-
ation between the infusion of factor VIII and the
development of these allo-antibodies has clearly linked
factor VIII products to inhibitors. The risk to develop
inhibitors is directly correlated to the number of expos-
ure days; they develop mainly in the first 50 exposure
days (EDs). Especially during the first 20 EDs there is a
steep rise, with 50 % of the inhibitors having developed
at 14–15 EDs [1, 2].
The availability of clotting products has an important
impact on treatment strategies and the age prophylaxis
is started. Plasma products were scarce in the seventies
and eighties and prophylaxis was only introduced in
countries such as Sweden and The Netherlands [3, 4].
Over the years these countries recognised that an early
start was crucial and they started prophylaxis at 1–2
years. In countries still using episodic treatment, inhibi-
tors were often diagnosed in adults after many years of
treatment. In the eighties with the fear of HIV, inhibitors
did not gather much attention, as physicians and pa-
tients were very careful in their dosing and in many
countries prophylactic treatment was still not introduced
[5]. After the large problems with viral pathogens trans-
mitted through plasma products, the introduction of re-
combinant products in the early nineties made it
possible to treat a new generation of children with
haemophilia with recombinant products without the fear
of transmitting pathogens. In the early nineties, an out-
break of inhibitors occurred in adult patients who were
treated for more than 150 EDs [6, 7]. This unusual event
urged the regulators to ask for stringent studies in previ-
ously untreated children (PUPs). In the past no formal
PUP studies with locally produced plasma products were
performed. In clinical trials frequent testing for inhibi-
tors was mandatory. Single positive laboratory tests in a
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patient were reported as inhibitors [8]. The high inhibi-
tor results in the first PUP studies with recombinant
products led to the discussion whether a higher risk for
inhibitors existed with recombinant products as com-
pared to plasma products. In the next paragraph the
most important factors influencing the comparison of
different studies are discussed.
Review
Risk factors for inhibitor development
In the last decade many new risk factors for inhibitor
development have been recognised. It is now commonly
accepted that inhibitor development is influenced by
multiple risk factors [9]. In general, these factors can be
divided in genetic and non-genetic risk factors. After
genetic analysis of the F8 gene became available, a clear
correlation was demonstrated between high-risk F8 gene
mutations and inhibitor development [10, 11]. The im-
portance of the causative mutation is further established
in a recent meta-analysis in severe haemophilia A by
Gouw et al. [12]. This confirmed that the inhibitor risks
in patients with large deletions were five times higher
than for nonsense mutations. However patients with in-
tron 22 inversions had an average risk.
Another study that shed new light on the impact of
the FVIII gene was the Insight study [13]. In this large
international study including patients with mild haemo-
philia, the overall risk for inhibitors clearly increased in
patients with more EDs. The inhibitor risk doubled be-
tween 50 and 100 EDs to > 13 %, which is much higher
than previously reported [13].
Afro-American ethnicity was correlated with up to
50 % risk; but this needs to be confirmed in larger
studies [11].
Studies on polymorphisms in immune regulatory
genes explored a more mechanistic approach between
genetic and non-genetic risk factors [9]. Especially T-cell
responses are important, but their exact role has been
difficult to establish due the small number of inhibitors
in studies.
Products
The best studied non-genetic risk factor is the prod-
uct used for treatment during the first 50EDs. Wight
and Paisley concluded in their 2003 review that the
risk for plasma products was lower [14]. From that
time onwards, many meta-analyses were performed
on newly published studies [15–17]. Overall, a lower
risk for class plasma products was concluded, al-
though the risk difference decreased over the years
[17]. Several academic groups recognised the short-
comings in the different study designs and the im-
portance to collect large amounts of data from many
different products [18, 19]. Large observational cohort
studies using the same definition for inhibitors did
not confirm a difference in inhibitor risk between
class plasma and class recombinant products [2, 19].
A very important non-genetic risk factor is the effect
of high dosing and intensive treatment [20–24]. Studies
have demonstrated that inhibitor risk can increase trice
during periods of peak treatment. In the meantime, the
increased availability of products and the small vial sizes
of recombinant products made it much easier to in-
crease dosing in small children.
The potential role of von Willebrand factor (VWF) as
an immune protective chaperone for FVIII is not clear,
but it may act through antigenic competition and/or by
reducing endocytosis of the FVIII molecule in a dose-
dependent manner, thereby preventing activation of im-
mune effectors [24].
An unexpected observation was a higher inhibitor
risk for a specific second generation recombinant
product [19]. This observation was confirmed in two
other independent studies [25, 26]. The strengths of
these studies are that they included all eligible pa-
tients and followed them until at least 50EDs and
that they all used the same definition for clinically
relevant inhibitors. This gives a more appropriate
overall risk and enables comparison between prod-
ucts. A weakness is that not all inhibitor samples are
confirmed in a central laboratory, which could lead to
misdiagnosis in low-titre inhibitors.
To give a definitive answer about whether there is a
risk difference between class plasma and class recombin-
ant products, the SIPPET study was performed a rando-
mised controlled study between class plasma and class
recombinant products in circa 250 PUPs with severe
haemophilia A [27]. It was concluded that plasma prod-
ucts had a significantly lower risk than recombinant
products [27]. Although the RCT design is the most
preferable one for comparison of 2 products or 2 strat-
egies, it is debatable what the outcome of this study
means for the current choice of products.
The first non-genetic risk factor that was deter-
mined was the age at first exposure to FVIII [28].
Start of treatment before 6 months of age significantly
increased the risk. This association could be largely
explained by early, intensive treatment for major
bleeds and surgery [2, 29]. Another very interesting
observation was the lower inhibitor risk in patients
who received prophylaxis from an early age onwards
[2, 29]. During prophylactic treatment, patients are
exposed to factor VIII in the absence of intensive
treatment and tissue damage. While several studies
have confirmed the effect, the difference in study de-
sign and the short period until inhibitor development
presently hinders a definitive conclusion regarding the
preventive effect of prophylaxis [30].
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Impact of inhibitor testing
The definition of inhibitors was historically based on the
lack of response to treatment. Bleedings were unrespon-
sive and the clinical symptoms pointing at an inhibitor
were confirmed by a positive Bethesda assay. After the
introduction of recombinant products and the results of
the clinical PUP studies that reported inhibitors in 25–
35 % of PUPs, regular testing to detect inhibitors became
the norm. Nowadays it is recommended to test at least
every 3 months for inhibitors during the first 50 EDs
[31]. In a large study, the PedNet group divided all PUPs
according to 5-year birth cohorts [32]. Over a 20-year
period, inhibitor titres over a 20-year period where in-
vestigated in 926 PUPs with severe haemophilia. The
strength of the study is that the same definition of inhib-
itors is used and that all patients were followed until 50
EDs. The total inhibitor incidence increased from 19.5 %
in 1990–1994 to 30.9 % in 2000–2004 (p 0.011). This
was solely due to the detection of more low-titre inhibi-
tors, increasing from 3.1 % to 10.5 % (P = 0.009) [32].
Discussion
Inhibitor development is currently the most serious side
effect of the treatment with clotting factor products. It is
caused by the interplay of many risk factors [9]. Since in-
hibitors only develop after treatment has been started, a
direct correlation with the type of clotting product was
expected. In the early 1990s the awareness for inhibitors
has increased after the outbreak of inhibitors on certain
plasma products [6, 7]. At the same time recombinant
products were registered according to stringent proce-
dures, and authorities demanded frequent testing for in-
hibitors [8]. The coincidence of these occurrences has
probably led to the assumption of a higher risk for re-
combinant products.
To rule out any confounding factors, the SIPPET study
was performed [27]. This study found a higher risk for
recombinant products. Since the study was performed
mostly in other geographical areas and was prematurely
stopped, the impact on future treatment choice is
unclear. EMA and FDA have taken the results seriously
and requested to review all data (http://www.ema.euro-
pa.eu/docs/en_GB/document_library/Referrals_documen
t/Factor_VIII_31/Procedure_started/WC500209984.pdf ).
From a pharmacological point of view it is doubtful if a
comparison between class products will lead to clinically
meaningful results. Products are all different and the ef-
fects of any product should be investigated separately.
Factors that may influence the results of studies are
numerous. The most important factors are the small
numbers of subject in many studies. It is clear that at
the time of marketing authorisation, the safely profile of
clotting products is not completely clear. Especially for
immunogenicity, large data in PUPS needs to be
collected. The World Federation of Hemophilia has ac-
knowledged this and introduced templates for data col-
lection to be used by haemophilia centres [33]. It is
especially advisable that centres collect data on all PUPs
with severe and moderate haemophilia and share the re-
sults. There is even a larger need with all the new prod-
ucts that will be marketed. Independent comparison of
products is only possible when the data collected is simi-
lar and includes all confounding factors.
The importance of central testing is clear; it can
largely reduce laboratory variations. It has to be weighed
against missing samples in small children, which will
affect the outcome of studies as well. The emphasis has
been too much on the single laboratory tests. Other fac-
tors should be included as well, such as reduced recov-
ery and clinical signs of bleeding. The definition of a
clinical important inhibitor, excluding single positive la-
boratory tests, has been proven to be of great import-
ance. Overall more low-titre inhibitors have been
detected [8, 32]. Interestingly, many of the on-going
large prospective observational studies, despite not hav-
ing performed central testing, still have found very simi-
lar results for high-titre inhibitor incidences [2, 18, 19].
Conclusion
In conclusion, inhibitor development is a major side
effect of treatment. All current products have an un-
acceptable high risk for inhibitors and large international
collaborations are needed to Improve the mechanism of
inhibitor formation.
Key points
 High titre inhibitors should be the primary outcome
 Currently all factor VIII products have a large risk of
inhibitor development
 Further studies are needed to confirm a lower risk
for any particular FVIII product
 Large international collaborations between all
stakeholders should address the inhibitor problem
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